-+ 0.00%
-+ 0.00%
-+ 0.00%

Johnson & Johnson’s Phase 4 STAR Study Of TREMFYA Meets Met Primary And Major Secondary Endpoints In Biologic-Naïve Adults With Active Psoriatic Arthritis And Axial Involvement

Benzinga·11/20/2026 13:02:51
Listen to the news
  • TREMFYA showed statistically significant improvement in disease activity on the BASDAI score versus placebo, reflecting meaningful reductions in pain, stiffness, swelling and fatigue in a Phase 4 study
  • TREMFYA demonstrated more than 2 times greater reduction in MRI-assessed inflammation versus placebo at Week 24 in the sacroiliac joints, which connect the lower spine to the pelvis and are responsible for pain and stiffness
  • TREMFYA was evaluated in first-ever PsA study using objective MRI assessments to confirm and measure axial inflammation alongside patient-reported symptoms

NEW BRUNSWICK, N.J., Nov. 20, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced late-breaking results from the Phase 4 STAR study of TREMFYA (guselkumab) in biologic-naïve adults with active psoriatic arthritis and axial involvement (axial PsA). TREMFYA met primary and major secondary endpoints that demonstrated significant improvement in axial symptoms compared to placebo and significant reduction of MRI-assessed inflammation in the sacroiliac joints.1,a The Phase 4 STAR study is the first and only dedicated randomized, double-blind, placebo-controlled study designed to prospectively evaluate an IL-23 inhibitor specifically in patients with axial involvement in PsA confirmed by magnetic resonance imaging (MRI). The late-breaking results are being presented at the Emirates Society for Rheumatology (ESR) Annual Meeting.